BR0214023A - Derivados de 1,2,4-tiadiazólio como moduladores de receptor de melanocortina - Google Patents
Derivados de 1,2,4-tiadiazólio como moduladores de receptor de melanocortinaInfo
- Publication number
- BR0214023A BR0214023A BR0214023-3A BR0214023A BR0214023A BR 0214023 A BR0214023 A BR 0214023A BR 0214023 A BR0214023 A BR 0214023A BR 0214023 A BR0214023 A BR 0214023A
- Authority
- BR
- Brazil
- Prior art keywords
- melanocortin receptor
- receptor modulators
- thiadiazole derivatives
- derivatives
- useful
- Prior art date
Links
- 102000004378 Melanocortin Receptors Human genes 0.000 title abstract 2
- 108090000950 Melanocortin Receptors Proteins 0.000 title abstract 2
- YGTAZGSLCXNBQL-UHFFFAOYSA-N 1,2,4-thiadiazole Chemical class C=1N=CSN=1 YGTAZGSLCXNBQL-UHFFFAOYSA-N 0.000 title 1
- 125000003342 alkenyl group Chemical group 0.000 abstract 1
- 125000000217 alkyl group Chemical group 0.000 abstract 1
- 125000000304 alkynyl group Chemical group 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 239000000336 melanocortin receptor agonist Substances 0.000 abstract 1
- 230000002503 metabolic effect Effects 0.000 abstract 1
- 239000002464 receptor antagonist Substances 0.000 abstract 1
- 229940044551 receptor antagonist Drugs 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
- C07D285/01—Five-membered rings
- C07D285/02—Thiadiazoles; Hydrogenated thiadiazoles
- C07D285/04—Thiadiazoles; Hydrogenated thiadiazoles not condensed with other rings
- C07D285/08—1,2,4-Thiadiazoles; Hydrogenated 1,2,4-thiadiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/10—Anti-acne agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/007—Preparations for dry skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q5/00—Preparations for care of the hair
- A61Q5/006—Antidandruff preparations
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
- C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
- C07D333/06—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring carbon atoms
- C07D333/14—Radicals substituted by singly bound hetero atoms other than halogen
- C07D333/16—Radicals substituted by singly bound hetero atoms other than halogen by oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/28—Phosphorus compounds with one or more P—C bonds
- C07F9/38—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)]
- C07F9/40—Esters thereof
- C07F9/4003—Esters thereof the acid moiety containing a substituent or a structure which is considered as characteristic
- C07F9/4018—Esters of cycloaliphatic acids
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Diabetes (AREA)
- Dermatology (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Neurology (AREA)
- Ophthalmology & Optometry (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Reproductive Health (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Epidemiology (AREA)
- Birds (AREA)
- Emergency Medicine (AREA)
- Psychiatry (AREA)
- Gynecology & Obstetrics (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Child & Adolescent Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
Abstract
"DERIVADOS DE 1,2,4-TIADIAZóLIO COMO MODULADORES DE RECEPTOR DE MELANOCORTINA". A presente invenção refere-se a derivados de 1,2,4-tiadiazol-2-io da fórmula (1): onde R^ 1^, R^ 2^ e R^ 4^ são radicais contendo anel, e R^ 3^ é H, alquila, alquenila ou alquinila, úteis como agonistas ou antagonistas do receptor de melanocortina. Mais particularmente, os compostos da presente invenção são úteis para o tratamento de distúrbios metabólicos, do SNC e dermatológicos.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US33776201P | 2001-11-08 | 2001-11-08 | |
PCT/US2002/035365 WO2003040118A1 (en) | 2001-11-08 | 2002-11-05 | Novel 1,2,4-thiadiazolium derivatives as melanocortin receptor modulators |
Publications (1)
Publication Number | Publication Date |
---|---|
BR0214023A true BR0214023A (pt) | 2004-11-23 |
Family
ID=23321888
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR0214023-3A BR0214023A (pt) | 2001-11-08 | 2002-11-05 | Derivados de 1,2,4-tiadiazólio como moduladores de receptor de melanocortina |
Country Status (25)
Country | Link |
---|---|
US (4) | US7319107B2 (pt) |
EP (1) | EP1444215B1 (pt) |
JP (1) | JP4491235B2 (pt) |
CN (1) | CN100422164C (pt) |
AR (1) | AR037284A1 (pt) |
AT (1) | ATE333449T1 (pt) |
AU (1) | AU2002340372B2 (pt) |
BR (1) | BR0214023A (pt) |
CA (1) | CA2466145A1 (pt) |
CY (1) | CY1105233T1 (pt) |
DE (1) | DE60213276T2 (pt) |
DK (1) | DK1444215T3 (pt) |
ES (1) | ES2268108T3 (pt) |
IL (2) | IL161830A0 (pt) |
MX (1) | MXPA04004457A (pt) |
MY (1) | MY134994A (pt) |
NO (1) | NO328194B1 (pt) |
NZ (1) | NZ532884A (pt) |
PT (1) | PT1444215E (pt) |
RS (1) | RS51199B (pt) |
RU (1) | RU2323932C2 (pt) |
SI (1) | SI1444215T1 (pt) |
TW (1) | TWI317358B (pt) |
WO (1) | WO2003040118A1 (pt) |
ZA (1) | ZA200404487B (pt) |
Families Citing this family (65)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7655658B2 (en) | 2001-08-10 | 2010-02-02 | Palatin Technologies, Inc. | Thieno [2,3-D]pyrimidine-2,4-dione melanocortin-specific compounds |
US7718802B2 (en) | 2001-08-10 | 2010-05-18 | Palatin Technologies, Inc. | Substituted melanocortin receptor-specific piperazine compounds |
AU2002331064B2 (en) | 2001-08-10 | 2007-08-23 | Palatin Technologies, Inc. | Peptidomimetics of biologically active metallopeptides |
US7456184B2 (en) | 2003-05-01 | 2008-11-25 | Palatin Technologies Inc. | Melanocortin receptor-specific compounds |
US7732451B2 (en) | 2001-08-10 | 2010-06-08 | Palatin Technologies, Inc. | Naphthalene-containing melanocortin receptor-specific small molecule |
US7319107B2 (en) * | 2001-11-08 | 2008-01-15 | Johnson & Johnson Consumer Companies, Inc. | 1,2,4-thiadiazolium derivatives as melanocortin receptor modulators |
PT1446394E (pt) * | 2001-11-08 | 2007-01-31 | Ortho Mcneil Pharm Inc | Novos derivados de 1,2,4-tiadiazole como moduladores do receptor da melanocortina |
US7727990B2 (en) | 2003-05-01 | 2010-06-01 | Palatin Technologies, Inc. | Melanocortin receptor-specific piperazine and keto-piperazine compounds |
US7968548B2 (en) * | 2003-05-01 | 2011-06-28 | Palatin Technologies, Inc. | Melanocortin receptor-specific piperazine compounds with diamine groups |
US7727991B2 (en) | 2003-05-01 | 2010-06-01 | Palatin Technologies, Inc. | Substituted melanocortin receptor-specific single acyl piperazine compounds |
US8460243B2 (en) * | 2003-06-10 | 2013-06-11 | Abbott Diabetes Care Inc. | Glucose measuring module and insulin pump combination |
US7722536B2 (en) * | 2003-07-15 | 2010-05-25 | Abbott Diabetes Care Inc. | Glucose measuring device integrated into a holster for a personal area network device |
JP2007523197A (ja) * | 2004-02-23 | 2007-08-16 | プロレキシーズ ファーマシューティカルズ インコーポレイテッド | pHSP20様活性を有する非ペプチジル剤、およびその使用 |
EP1734963A4 (en) | 2004-04-02 | 2008-06-18 | Merck & Co Inc | METHOD FOR TREATING PEOPLE WITH METABOLIC AND ANTHROPOMETRIC DISORDER |
US7709484B1 (en) | 2004-04-19 | 2010-05-04 | Palatin Technologies, Inc. | Substituted melanocortin receptor-specific piperazine compounds |
CA2858901C (en) | 2004-06-04 | 2024-01-16 | Carolyn Anderson | Diabetes care host-client architecture and data management system |
US20070021433A1 (en) | 2005-06-03 | 2007-01-25 | Jian-Qiang Fan | Pharmacological chaperones for treating obesity |
US20070016256A1 (en) | 2005-07-18 | 2007-01-18 | Korb Donald R | Method and apparatus for treating gland dysfunction |
US20080114423A1 (en) | 2006-05-15 | 2008-05-15 | Grenon Stephen M | Apparatus for inner eyelid treatment of meibomian gland dysfunction |
US20090043365A1 (en) * | 2005-07-18 | 2009-02-12 | Kolis Scientific, Inc. | Methods, apparatuses, and systems for reducing intraocular pressure as a means of preventing or treating open-angle glaucoma |
US8950405B2 (en) | 2006-05-15 | 2015-02-10 | Tearscience, Inc. | Treatment of obstructive disorders of the eye or eyelid |
US20070060988A1 (en) * | 2005-07-18 | 2007-03-15 | Grenon Stephen M | Melting meibomian gland obstructions |
US7981145B2 (en) * | 2005-07-18 | 2011-07-19 | Tearscience Inc. | Treatment of meibomian glands |
US7981095B2 (en) | 2005-07-18 | 2011-07-19 | Tearscience, Inc. | Methods for treating meibomian gland dysfunction employing fluid jet |
WO2013003594A2 (en) | 2011-06-28 | 2013-01-03 | Tearscience, Inc. | Methods and systems for treating meibomian gland dysfunction using radio-frequency energy |
US7981146B2 (en) * | 2006-05-15 | 2011-07-19 | Tearscience Inc. | Inner eyelid treatment for treating meibomian gland dysfunction |
US8128674B2 (en) | 2006-05-15 | 2012-03-06 | Tearscience, Inc. | System for outer eyelid heat and pressure treatment for treating meibomian gland dysfunction |
US8137390B2 (en) * | 2006-05-15 | 2012-03-20 | Tearscience, Inc. | System for providing heat treatment and heat loss reduction for treating meibomian gland dysfunction |
US8527313B2 (en) * | 2006-05-15 | 2013-09-03 | Sap Ag | Document instantiation triggering a business action |
US8007524B2 (en) * | 2006-05-15 | 2011-08-30 | Tearscience, Inc. | Heat treatment and heat loss reduction for treating meibomian gland dysfunction |
US8128673B2 (en) | 2006-05-15 | 2012-03-06 | Tearscience, Inc. | System for inner eyelid heat and pressure treatment for treating meibomian gland dysfunction |
US9314369B2 (en) | 2006-05-15 | 2016-04-19 | Tearscience, Inc. | System for inner eyelid treatment of meibomian gland dysfunction |
US7976573B2 (en) * | 2006-05-15 | 2011-07-12 | Tearscience, Inc. | Inner eyelid heat and pressure treatment for treating meibomian gland dysfunction |
US7981147B2 (en) * | 2006-05-15 | 2011-07-19 | Tearscience, Inc. | Outer eyelid heat and pressure treatment for treating meibomian gland dysfunction |
US7834017B2 (en) | 2006-08-11 | 2010-11-16 | Palatin Technologies, Inc. | Diamine-containing, tetra-substituted piperazine compounds having identical 1- and 4-substituents |
WO2008027069A1 (en) * | 2006-08-21 | 2008-03-06 | Tearscience, Inc. | Method and apparatus for treating meibomian gland dysfunction employing fluid |
USD613408S1 (en) | 2008-02-06 | 2010-04-06 | Tearscience, Inc. | Eye treatment head gear |
USD617443S1 (en) | 2008-02-06 | 2010-06-08 | Tearscience, Inc. | Eye treatment goggles |
ES2453640T3 (es) | 2008-02-21 | 2014-04-08 | Janssen Pharmaceutica N.V. | Métodos para el tratamiento de desordenes dermatológicos |
US8377925B2 (en) | 2008-02-29 | 2013-02-19 | Mimetica Pty Ltd | Methods of modulating the activity of the MC5 receptor and treatment of conditions related to this receptor |
US8343958B2 (en) | 2008-02-29 | 2013-01-01 | Mimetica Pty Ltd | 3-aminoalkyl-1,4-diazepan-2-one melanocortin-5-receptor antagonists |
US8008291B2 (en) * | 2008-02-29 | 2011-08-30 | Mimetica Pty Ltd | 3-aminoalkyl-1,4-diazepan-2-one melanocortin-5 receptor antagonists |
CA2743489A1 (en) | 2008-11-17 | 2010-05-20 | Merck Sharp & Dohme Corp. | Substituted bicyclic amines for the treatment of diabetes |
CA2995880C (en) | 2009-01-16 | 2021-01-05 | Exelixis, Inc. | Processes for preparing n-(4-{[6,7-bis(methyloxy)quinolin-4-yl]oxy}phenyl)-n'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide |
BRPI1013853A2 (pt) * | 2009-04-24 | 2019-09-24 | Janssen Pharmaceuticals Inc | composições tópicas estáveis de derivados de 1,2,4-tiadiazol |
WO2011011506A1 (en) | 2009-07-23 | 2011-01-27 | Schering Corporation | Spirocyclic oxazepine compounds as stearoyl-coenzyme a delta-9 desaturase inhibitors |
WO2011011508A1 (en) | 2009-07-23 | 2011-01-27 | Schering Corporation | Benzo-fused oxazepine compounds as stearoyl-coenzyme a delta-9 desaturase inhibitors |
ES2360783B1 (es) * | 2009-10-02 | 2012-07-04 | Consejo Superior De Investigaciones Científicas (Csic) | 1,2,4-tiadiazoles-5-imino sustituidos utiles en el tratamiento de enfermedades neurodegenerativas |
USD638128S1 (en) | 2009-10-06 | 2011-05-17 | Tearscience, Inc. | Ocular device design |
EP2563764B1 (en) | 2010-04-26 | 2015-02-25 | Merck Sharp & Dohme Corp. | Novel spiropiperidine prolylcarboxypeptidase inhibitors |
US9365539B2 (en) | 2010-05-11 | 2016-06-14 | Merck Sharp & Dohme Corp. | Prolylcarboxypeptidase inhibitors |
WO2011156246A1 (en) | 2010-06-11 | 2011-12-15 | Merck Sharp & Dohme Corp. | Novel prolylcarboxypeptidase inhibitors |
EP2628734A4 (en) * | 2010-10-15 | 2014-04-23 | Federalnoe G Bydzhetnoe Uchrezhdenie Nauki Inst Fiziol Aktivnikh Veschestv Rossiiskoi Akademii Nauk | DERIVATIVES OF 5-AMINO - [1,2,4] THIADIAZOLE |
US9018395B2 (en) | 2011-01-27 | 2015-04-28 | Université de Montréal | Pyrazolopyridine and pyrazolopyrimidine derivatives as melanocortin-4 receptor modulators |
US10136845B2 (en) | 2011-02-28 | 2018-11-27 | Abbott Diabetes Care Inc. | Devices, systems, and methods associated with analyte monitoring devices and devices incorporating the same |
EP2683376B1 (en) * | 2011-03-07 | 2018-11-28 | Celgene Corporation | Methods for treating diseases using isoindoline compounds |
PL3539551T3 (pl) | 2011-12-29 | 2022-02-21 | Rhythm Pharmaceuticals, Inc. | Sposób leczenia zaburzeń związanych z receptorem melanokortyny 4 u heterozygotycznych nosicieli |
US10842670B2 (en) | 2012-08-22 | 2020-11-24 | Johnson & Johnson Vision Care, Inc. | Apparatuses and methods for diagnosing and/or treating lipid transport deficiency in ocular tear films, and related components and devices |
US9763827B2 (en) | 2013-04-30 | 2017-09-19 | Tear Film Innovations, Inc. | Systems and methods for the treatment of eye conditions |
ES2942724T3 (es) | 2013-04-30 | 2023-06-06 | Alcon Inc | Sistemas para el tratamiento de enfermedades del ojo |
JP6714589B2 (ja) | 2014-10-31 | 2020-06-24 | リポテック, エセ.ア. | Pseudoalteromonas antarctica由来の細菌性細胞外生成物を含有する化粧品組成物および/または医薬組成物ならびにその使用 |
CA3000670A1 (en) | 2015-09-30 | 2017-04-06 | Rhythm Pharmaceuticals, Inc. | Method of treating melanocortin-4 receptor pathway-associated disorders |
US10974063B2 (en) | 2016-06-30 | 2021-04-13 | Alcon Inc. | Light therapy for eyelash growth |
WO2019195756A1 (en) | 2018-04-06 | 2019-10-10 | Rhythm Pharmaceuticals, Inc. | Compositions for treating kidney disease |
CN115381955B (zh) * | 2021-05-24 | 2024-05-17 | 中国科学技术大学 | 黑皮质素受体mc5r的用途 |
Family Cites Families (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE131373C (pt) | ||||
DD131373A1 (de) | 1977-06-17 | 1978-06-21 | Juergen Liebscher | Verfahren zur herstellung von 2,3-disubstituierten 5-dialkylamino-1,2,4-thiadiazoliumsalzen |
JPS6011481A (ja) | 1983-06-30 | 1985-01-21 | Nippon Soda Co Ltd | 1,2,4−チアジアゾ−ル系誘導体及び農園芸用殺菌剤 |
JPH02173165A (ja) | 1988-12-27 | 1990-07-04 | Nippon Soda Co Ltd | 防汚剤 |
DE69708198T2 (de) * | 1996-04-30 | 2002-03-28 | Pfizer Inc., New York | Muscarinische Rezeptor-Agonisten |
US20020103194A1 (en) * | 1997-04-30 | 2002-08-01 | Anabella Villalobos | Novel muscarinic receptor agonists |
EP1076649A4 (en) | 1998-04-28 | 2010-06-02 | Trega Biosciences Inc | ISOQUINOLINE-BASED COMPOUNDS IN PLACE OF MELANOCORTIN RECEPTOR LIGANDS AND METHODS OF USE |
DE59913665D1 (de) * | 1998-04-29 | 2006-08-24 | Merck Patent Gmbh | Verfahren zur katalytischen herstellung von substituierten bipyridylderivaten |
AU742425B2 (en) | 1998-06-11 | 2002-01-03 | Merck & Co., Inc. | Spiropiperidine derivatives as melanocortin receptor agonists |
US6294534B1 (en) | 1998-06-11 | 2001-09-25 | Merck & Co., Inc. | Spiropiperidine derivatives as melanocortin receptor agonists |
AU1324300A (en) | 1998-10-26 | 2000-05-15 | Vertex Pharmaceuticals Incorporated | Pentacyclic compounds useful as inhibitors of hepatitis c virus ns3 helicase |
AU2001228681A1 (en) | 2000-01-28 | 2001-08-07 | Melacure Therapeutics Ab | Novel aromatic amines and amides acting on the melanocortin receptors |
JP2003527444A (ja) * | 2000-03-23 | 2003-09-16 | メルク エンド カムパニー インコーポレーテッド | メラノコルチン受容体アゴニストとして作用するスピロピペリジン誘導体 |
US6728804B1 (en) | 2000-10-27 | 2004-04-27 | Emware, Inc. | Remotely reprogrammable communications adapter for providing access to an electronic device |
US7319107B2 (en) * | 2001-11-08 | 2008-01-15 | Johnson & Johnson Consumer Companies, Inc. | 1,2,4-thiadiazolium derivatives as melanocortin receptor modulators |
PT1446394E (pt) | 2001-11-08 | 2007-01-31 | Ortho Mcneil Pharm Inc | Novos derivados de 1,2,4-tiadiazole como moduladores do receptor da melanocortina |
US7435429B2 (en) * | 2002-02-07 | 2008-10-14 | Trustees Of Columbia University In The City Of New York | Zinc salt compositions for the prevention of dermal and mucosal irritation |
ES2453640T3 (es) * | 2008-02-21 | 2014-04-08 | Janssen Pharmaceutica N.V. | Métodos para el tratamiento de desordenes dermatológicos |
BRPI1013853A2 (pt) * | 2009-04-24 | 2019-09-24 | Janssen Pharmaceuticals Inc | composições tópicas estáveis de derivados de 1,2,4-tiadiazol |
-
2002
- 2002-11-04 US US10/287,096 patent/US7319107B2/en not_active Expired - Fee Related
- 2002-11-05 NZ NZ532884A patent/NZ532884A/en not_active IP Right Cessation
- 2002-11-05 BR BR0214023-3A patent/BR0214023A/pt active Search and Examination
- 2002-11-05 JP JP2003542164A patent/JP4491235B2/ja not_active Expired - Fee Related
- 2002-11-05 AT AT02778727T patent/ATE333449T1/de active
- 2002-11-05 IL IL16183002A patent/IL161830A0/xx unknown
- 2002-11-05 CA CA002466145A patent/CA2466145A1/en not_active Abandoned
- 2002-11-05 PT PT02778727T patent/PT1444215E/pt unknown
- 2002-11-05 RS YUP-396/04A patent/RS51199B/sr unknown
- 2002-11-05 EP EP02778727A patent/EP1444215B1/en not_active Expired - Lifetime
- 2002-11-05 SI SI200230407T patent/SI1444215T1/sl unknown
- 2002-11-05 DE DE60213276T patent/DE60213276T2/de not_active Expired - Lifetime
- 2002-11-05 RU RU2004114208/04A patent/RU2323932C2/ru not_active IP Right Cessation
- 2002-11-05 CN CNB028268989A patent/CN100422164C/zh not_active Expired - Fee Related
- 2002-11-05 WO PCT/US2002/035365 patent/WO2003040118A1/en active IP Right Grant
- 2002-11-05 MX MXPA04004457A patent/MXPA04004457A/es active IP Right Grant
- 2002-11-05 DK DK02778727T patent/DK1444215T3/da active
- 2002-11-05 AU AU2002340372A patent/AU2002340372B2/en not_active Ceased
- 2002-11-05 ES ES02778727T patent/ES2268108T3/es not_active Expired - Lifetime
- 2002-11-07 AR ARP020104271A patent/AR037284A1/es not_active Application Discontinuation
- 2002-11-08 TW TW091133318A patent/TWI317358B/zh not_active IP Right Cessation
- 2002-11-08 MY MYPI20024180A patent/MY134994A/en unknown
-
2004
- 2004-05-06 IL IL161830A patent/IL161830A/en not_active IP Right Cessation
- 2004-06-07 NO NO20042373A patent/NO328194B1/no not_active IP Right Cessation
- 2004-06-07 ZA ZA200404487A patent/ZA200404487B/en unknown
-
2005
- 2005-09-27 US US11/236,097 patent/US20060030604A1/en not_active Abandoned
-
2006
- 2006-09-15 CY CY20061101325T patent/CY1105233T1/el unknown
-
2008
- 2008-08-05 US US12/221,900 patent/US7786311B2/en not_active Expired - Fee Related
-
2010
- 2010-07-13 US US12/835,220 patent/US8501791B2/en not_active Expired - Fee Related
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR0214023A (pt) | Derivados de 1,2,4-tiadiazólio como moduladores de receptor de melanocortina | |
BR0214024A (pt) | Derivados de 1,2,4-tiadiazol como moduladores de receptor de melanocortina | |
BR0312999A (pt) | Compostos, composições farmacêticas, método para aumentar a cognição, de tratamento, de inibição da atividade de enzima pde4 em um paciente | |
BR0312575A (pt) | Moduladores do receptor de glicocorticóides | |
BR0009320A (pt) | Dibenzopiranos como antagonistas do receptor glicocorticóide para o tratamento da diabete | |
BR0012697A (pt) | Inibidores da diferenciação de th2 | |
BR0014761A (pt) | Derivados de benzodiazepina | |
BR0311494A (pt) | Novos indóis substituìdos | |
BR9915420A (pt) | Composto, composição farmacêutica, métodos de tratar um distúrbio mediado por tnf e por p38 cinase, inflamação e artrite e processo de preparar pirazóis | |
UY26130A1 (es) | Compuestos para tratar la obesidad | |
BR0312729A (pt) | Novos derivados de indol-3-enxofre | |
NO20032208D0 (no) | Benzodiazepinderivater som GABA A reseptormodulatorer | |
BR9910029A (pt) | Hidróxi indóis, sua aplicação como inibidores da fosfodiesterase 4 e processo para sua preparação | |
BRPI0408369A (pt) | derivados de indol úteis para o tratamento de doenças | |
TNSN02012A1 (fr) | Derives de pyrimidine nouveaux inhibiteurs de mmp, et compositions les contenant | |
BR0308787A (pt) | Inibidores de metaloproteinase de n-substituìdos-heteroarilóxi-aril-espiro-pirimidina- 2,4,6-triona | |
BR0311541A (pt) | indol, azaindol e 4-aquenil piperidina amidas heterocìclicas relacionadas | |
BR0206943A (pt) | Inibidores de fosfodiesterase 4 | |
BR0206633A (pt) | Derivados de 1-aril- ou 1-arilsulfonilbenzazol como ligandos de 5-hidroxitriptamina-6 | |
BR0206738A (pt) | Derivados tricìclicos de lactama e de sultama e uso dos mesmos como inibidores de histona desacetilase | |
BR9808366A (pt) | Derivados de ácido hidroxâmico substituìdo com aril ou heteroaril sulfonamidas; processo para sua preparação e seu uso como produtos farmacêuticos | |
BR0112093A (pt) | Derivados de sulfonil-pirrolidina úteis no tratamento de distúrbios neurológicos | |
BR0213094A (pt) | Derivados de cromano como ligandos de 5-hidroxi-triptamina-6 | |
BR0316723A (pt) | Derivados de anilinopirazol úteis para o tratamento de diabetes | |
DK0982992T3 (da) | Anvendelse af thienopyrimidiner som fungicider |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B25A | Requested transfer of rights approved |
Owner name: JOHNSON AND JOHNSON (US) Free format text: TRANSFERIDO DE: ORTHO-MC NEIL PHARMACEUTICAL, INC. |
|
B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 14A ANUIDADE. |
|
B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2386 DE 27-09-2016 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013. |
|
B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] |